CD274 and esophageal squamous cell carcinoma: In the KEYNOTE-181 trial, pembrolizumab improved median overall survival (OS) to 12.5 months in ESCC patients with PD-L1 combined positive score (CPS) ≥10, compared to 10.0 months in the overall cohort (2).